CBG

CBG

New studies make a case for topical CBD absorption and pain management

There is a great demand for topical analgesics. According to recent statistics, the global topical analgesics market targeting mild to moderate pain is worth $10.26 billion. Many topical pain agents were originally developed as oral or injected drugs and later reformulated in a dosage more suited to topical administration (e.g., creams, gels, ointments). These include salicylates, nonsteroidal anti-inflammatory drugs (NSAIDs), capsaicinoids, corticosteroids and opioids. Physicians currently recommend these medicines to treat localized eczema, contact dermatitis, psoriasis, abrasions, muscle aches, etc. Given their …
CBG

CBG in Focus

CBG Discovery Cannabigerol (CBG), 'the mother of all cannabinoids', is a rare non-psychoactive cannabinoid. It was first isolated in 1964 by Raphael Mechoulam, the father of cannabinoids, and his colleagues Yechiel Gaoni and Yuval Shvo from the Weizmann Institute in Rehovot (Israel); one of the world’s leading multidisciplinary basic research institutions in the natural and exact sciences. Since then researchers mostly focused on the Cannabidiol (CBD) and Tetrahydrocannabinol (THC), so most research on CBG happened in the past decade. CBG Research While the …